Retatrutide is a triple agonist targeting GLP-1, GIP, and glucagon receptors, while Amycretin is a dual agonist targeting GLP-1 and amylin receptors
You lose fat without that skinny-fat look that comes from crash dieting
Whats novel about current medications is that they address more than one target or pathway in both these systems, working well to reduce hunger, enhance satiety, and facilitate lower intake leading to weight reduction
The design makes it easy to hide it under any clothing
We dug into the latest research and spoke with endocrinologists, obesity specialists and psychologists to understand what really happens when you stop taking one of these medications and how to make the transition as successfully as possible
How can working with a regular doctor increase your chance of insurance coverage compared to telehealth